COVID-19

  • Vanderbilt University

    New structure gives insight into mRNA export and cancers, and how viruses hijack the process to infect their host

    A newly determined structure from the lab of Yi Ren reveals information about the mRNA export pathway and suggests that herpes viruses could hijack that interaction to infect their host. The new structures also reveal how certain mutations in the protein complex could play a role in cancers. Read More

    Nov. 14, 2024

  • Vanderbilt University

    Supercomputing redesign of a COVID monoclonal antibody

    One of the monoclonal antibodies in the therapeutic Evusheld has been computationally redesigned to restore its action against Omicron variants of the virus that causes COVID-19. Read More

    May. 14, 2024

  • Vanderbilt University

    James Crowe awarded “TIME” Best Inventions of 2022

    Dr. James Crowe Jr., director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called  Evusheld is the first treatment… Read More

    Dec. 5, 2022

  • Dr. James Crowe Jr., professor of medicine, in his lab at Medical Research Building IV. Dr. Crowe is the subject of a feature article in the upcoming Winter 2018 issue of Vanderbilt Magazine. Crowe, who is the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology, as well as director of the Vanderbilt Vaccine Center, has spent his career hunting for a universal flu vaccine. He has re-engineered how flu vaccines work and is on the edge of creating a single shot that covers all flu strains. In a new initiative announced in October, he will lead an international team of researchers as they launch clinical trials of his new vaccine.(John Russell/Vanderbilt University)

    Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

    James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization, for his team’s role in developing human monoclonal antibodies and vaccine candidates against COVID-19. The award, which was announced Oct. 6,… Read More

    Oct. 7, 2022

  • Vanderbilt University

    Skaar et al land grant to build top-line biosafety facility

    Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. VUMC currently has two BSL3 labs, but they are small, outdated and… Read More

    Oct. 7, 2022

  • Vanderbilt University

    Resistance to COVID-19 drug detected in lab study

    The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism. The results of the laboratory study led by researchers at Vanderbilt University Medical Center and published April 28 in the journal Science… Read More

    May. 12, 2022

  • Vanderbilt University

    Resistance to COVID-19 drug detected in lab study

    The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism. The results of the laboratory study led by researchers at Vanderbilt University Medical Center and published April 28 in the journal Science… Read More

    May. 12, 2022

  • Vanderbilt University

    Crowe receives national award for COVID antibody research

    James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. The announcement was made… Read More

    Apr. 1, 2022

  • Vanderbilt University

    Zost honored for research on COVID-19, other life-threatening viral diseases

    Seth Zost, PhD, a research fellow in the laboratory of James E. Crowe Jr., MD, director of the Vanderbilt Vaccine Center, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. The Claude Hannoun Prize for Best Body of Work is… Read More

    Oct. 29, 2021